title: Efficacy and safety of moclobemide compared with imipramine in the treatment of major depressive disorder. Double-blind multicenter study, Austria.
abstract: In a double-blind, 4-week, prospective, randomized multicenter (17 centers) study we checked on the efficacy, tolerability and safety of moclobemide (300-600 mg/d) compared to imipramine (100-200 mg/d) in parallel groups of patients with a Major Depressive Episode (DSM III). The mean % reduction of the HAMD at the end of treatment was 51.7 in the moclobemide group and 52.1 in the imipramine group. The percentage of patients in whom efficacy was globally judged as "good" or "very good" was 62% in the moclobemide group and 60% in the imipramine group. There was no statistically significant difference in the efficacy in both groups but in some factors there was a trend for a better amelioration favoring moclobemide. The final overall physician's judgement of tolerability was "good" or "very good" in 83% of moclobemide patients and in 74% of imipramine patients. Adverse events were reported or observed in 56% of moclobemide patients and in 69% of imipramine patients. The number of mild, moderate and severe adverse events was higher in the imipramine group with a total of 286 versus 189. There was a statistically high significant difference considering the tolerability favoring moclobemide again. In this project the basic goal to find a substance with at least the same efficacy but a much better tolerability for sure got fulfilled.
authors.affiliation: NO Landes-Nervenklinik, Amstetten/Mauer, Switzerland.
authors.forename: G F
authors.initials: GF
authors.lastname: Hebenstreit
authors.forename: M
authors.initials: M
authors.lastname: Loidl
authors.forename: U
authors.initials: U
authors.lastname: Baumhackl
authors.forename: B
authors.initials: B
authors.lastname: Gallhofer
authors.forename: C
authors.initials: C
authors.lastname: Geretsegger
authors.forename: E
authors.initials: E
authors.lastname: Radmayr
authors.forename: M
authors.initials: M
authors.lastname: Saletu
authors.forename: W
authors.initials: W
authors.lastname: Schöny
authors.forename: M
authors.initials: M
authors.lastname: Stabl
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001317:Austria; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007099:Imipramine / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales
chemical_list: D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D007099:Imipramine; D020912:Moclobemide